Learn about the phase 3 pivotal trial program
PYRUKYND® (mitapivat) Tablets Commercial Prescription and myAgios Patient Support Services Enrollment
There are 2 ways to prescribe PYRUKYND and enroll your patients in the myAgios Patient Support Program.
You can complete the prescription for PYRUKYND online and it will be automatically directed to a myAgios Patient Support Manager (PSM). We will reach out to your patient to obtain their HIPAA release authorization and complete their enrollment in myAgios.
Have questions regarding filling out the online form?
You can download and fill out the Enrollment Form to request prescription fulfillment for eligible patients and connect them to a dedicated myAgios Patient Support Manager (PSM). myAgios will reach out to your patients who may not have completed their HIPAA authorization.
If assistance is needed in completing the Enrollment Form, please check out the myAgios Annotated Enrollment Form for step-by-step guidance on the prescription and enrollment process.
Fax the completed enrollment form to 1-800-951-7814.
You may also call myAgios at 1-800-951-3889 with questions, Mon-Fri, 8 am to 6 pm ET.
Once the form is completed and received by myAgios, your patient will be enrolled in myAgios and connected to a Patient Support Manager.
We will conduct a benefits investigation to check your patient’s insurance. Please call myAgios at 1-800-951-3889 with any questions.
Call myAgios Patient Support Services at 1-800-951-3889, Mon-Fri, 8 am to 6 pm ET.
PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
IMPORTANT SAFETY INFORMATION
Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.
Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.
- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
- Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
- Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
- UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
- P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.
Please see full Prescribing Information for PYRUKYND.